Detalhe da pesquisa
1.
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.
Cell
; 178(3): 699-713.e19, 2019 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31280963
2.
Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma.
Ann Hematol
; 102(12): 3445-3455, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37566280
3.
Neutropenia-related aspergillosis in non-transplant haematological patients hospitalised under ambient air versus purified air conditions.
Mycoses
; 66(6): 505-514, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36786491
4.
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
Br J Haematol
; 198(3): 482-491, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35362552
5.
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i).
Br J Haematol
; 196(3): 606-616, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34775591
6.
Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/ transformation.
Haematologica
; 107(9): 2144-2153, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35021600
7.
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(2): 223-234, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539742
8.
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.
Eur J Nucl Med Mol Imaging
; 48(11): 3550-3559, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33928400
9.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Lancet
; 393(10168): 229-240, 2019 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30522922
10.
Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation.
Blood
; 131(13): 1464-1475, 2018 03 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29348129
11.
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
Hematol Oncol
; 38(3): 244-256, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32067259
12.
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
Ann Hematol
; 98(4): 897-907, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30610279
13.
Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
Eur J Haematol
; 102(3): 241-250, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30471148
14.
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Lancet
; 390(10114): 2790-2802, 2017 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29061295
15.
Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.
Br J Haematol
; 198(2): 401-404, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35538912
16.
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.
Blood
; 124(26): 3870-9, 2014 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25359988
17.
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Lancet Oncol
; 16(16): 1691-9, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26549589
18.
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.
Blood
; 120(10): 2032-41, 2012 Sep 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-22493293
19.
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
J Clin Oncol
; 42(14): 1612-1618, 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38364196
20.
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
Blood
; 118(13): 3504-11, 2011 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-21715318